Neumora Therapeutics (NMRA) is trading up at $0.53 (+5.08%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
| FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|
| Income statement | ||||
| Operating income | −$135.9M | −$252.1M | −$263.5M | −$241.2M |
| Net income | −$130.9M | −$235.9M | −$243.8M | −$236.9M |
| EPS (diluted) | −$4.81 | −$3.63 | −$1.53 | −$1.45 |
| Balance sheet | ||||
| Cash and equivalents | $240.9M | $374.0M | $142.1M | $182.5M |
| Total assets | $426.2M | $496.2M | $317.0M | $191.0M |
| Total liabilities | $29.4M | $27.1M | $29.9M | $87.2M |
| Long-term debt | — | — | $0 | $54.5M |
| Shareholders' equity | −$446.9M | $469.1M | $287.1M | $103.9M |
| Cash flow | ||||
| Operating cash flow | −$114.9M | −$163.3M | −$182.9M | −$206.4M |
| Capital expenditure | $511.0K | $117.0K | — | — |
| Free cash flow | −$115.4M | −$163.4M | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$76.6M | −$62.9M | −$70.9M | −$54.0M | −$57.7M | −$58.5M | −$52.9M | −$42.2M |
| Net income | −$72.5M | −$58.8M | −$68.0M | −$52.7M | −$56.8M | −$59.5M | −$53.5M | −$43.1M |
| EPS (diluted) | −$0.45 | −$0.37 | −$0.42 | −$0.33 | −$0.35 | −$0.35 | −$0.30 | −$0.23 |
| Balance sheet | ||||||||
| Cash and equivalents | $275.7M | $142.1M | $126.9M | $124.5M | $129.1M | $182.5M | $147.1M | $116.8M |
| Total assets | $352.5M | $317.0M | $256.7M | $223.8M | $177.8M | $191.0M | $153.9M | $125.2M |
| Total liabilities | $31.8M | $29.9M | $28.4M | $40.9M | $45.7M | $87.2M | $83.2M | $80.7M |
| Long-term debt | — | $0 | — | $19.5M | $19.6M | $54.5M | $53.0M | $52.9M |
| Shareholders' equity | $320.7M | $287.1M | $228.4M | $182.9M | $132.2M | $103.9M | $70.7M | $44.5M |
| Cash flow | ||||||||
| Operating cash flow | −$33.5M | −$50.3M | −$59.4M | −$52.4M | −$46.6M | −$48.0M | −$46.4M | −$39.5M |
From Neumora Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Neumora Therapeutics in our feed yet.